Hippo Pathway in Neurodegeneration
Overview
Hippo Pathway In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, and tissue homeostasis. Originally discovered in Drosophila, this pathway has emerged as a critical regulator of neuronal survival, stem cell function, and neurodegeneration[@metabolic].
Introduction of the Hippo Pathway
Core Pathway Components
| Component | Function | Neurodegeneration Relevance |
|-----------|----------|---------------------------|
| MST1/2 (Hippo) | Kinase, activates LATS1/2 | Pro-apoptotic in [neurons](/cell-types/neurons) |
| SAV1 | Scaffold protein | Forms complex with MST1/2 |
| LATS1/2 | Kinase, phosphorylates YAP/TAZ | Tumor suppressor |
| MOB1A/B | Scaffold for LATS | Essential for kinase activity |
| YAP/TAZ | Transcriptional co-activators | Pro-survival when active |
| TEAD1-4 | Transcription factors | Partner YAP/TAZ |
Pathway Regulation
...Hippo Pathway in Neurodegeneration
Overview
Hippo Pathway In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, and tissue homeostasis. Originally discovered in Drosophila, this pathway has emerged as a critical regulator of neuronal survival, stem cell function, and neurodegeneration[@metabolic].
Introduction of the Hippo Pathway
Core Pathway Components
| Component | Function | Neurodegeneration Relevance |
|-----------|----------|---------------------------|
| MST1/2 (Hippo) | Kinase, activates LATS1/2 | Pro-apoptotic in [neurons](/cell-types/neurons) |
| SAV1 | Scaffold protein | Forms complex with MST1/2 |
| LATS1/2 | Kinase, phosphorylates YAP/TAZ | Tumor suppressor |
| MOB1A/B | Scaffold for LATS | Essential for kinase activity |
| YAP/TAZ | Transcriptional co-activators | Pro-survival when active |
| TEAD1-4 | Transcription factors | Partner YAP/TAZ |
Pathway Regulation
Mermaid diagram (expand to render)
Hippo Pathway in Alzheimer's Disease
Tau Pathology Connection
The Hippo pathway intersects with Alzheimer's disease through multiple mechanisms:
MST1 activation — [Tau](/proteins/tau) pathology activates MST1 kinase
YAP/TAZ sequestration — Phosphorylated YAP/TAZ trapped in cytoplasm
Reduced pro-survival signaling — Decreased TEAD target gene expression
Synaptic dysfunction — YAP regulates synaptic protein expressionKey Findings
- [TAU](/genes/mapt) pathology activates MST1 in neurons
- MST1 phosphorylates and degrades TAZ
- YAP nuclear translocation reduced in AD brain
- TEAD target genes downregulated in AD
Therapeutic Implications
| Target | Approach | Status |
|--------|----------|--------|
| MST1 inhibitors | Block pro-apoptotic kinase | Preclinical |
| YAP activators | Promote nuclear localization | Investigational |
| TEAD agonists | Enhance pro-survival transcription | Early research |
Hippo Pathway in Parkinson's Disease
Dopaminergic Neuron Vulnerability
The Hippo pathway plays a critical role in dopaminergic neuron survival:
MST1 activation — Environmental toxins activate MST1
YAP degradation — Reduced pro-survival signaling
[α-Synuclein](/proteins/alpha-synuclein) interaction — α-Syn affects Hippo pathway components
Mitochondrial stress — MST1 mediates stress responseKey Findings
- [LRRK2](/genes/lrrk2) mutations affect Hippo pathway
- [PINK1](/genes/pink1) deficiency dysregulates MST1
- YAP nuclear localization reduced in PD brain
- MST1 mediates 6-OHDA-induced apoptosis
Cross-Pathway Interactions
- [mTOR pathway](/mechanisms/mtor-signaling-neurodegeneration) — intersects with Hippo
- [Autophagy](/mechanisms/autophagy) — YAP regulates autophagic genes
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — stress activates MST1
Hippo Pathway in Amyotrophic Lateral Sclerosis
Motor Neuron Vulnerability
ALS shows specific Hippo pathway dysregulation:
MST1 hyperactivation — In motor neurons
YAP cytoplasmic retention — Reduced survival signaling
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology — Affects Hippo pathway gene expression
FUS mutations — Disrupt Hippo pathway regulationKey Findings
- MST1 activation in ALS motor neurons
- Reduced YAP/TAZ nuclear localization
- TEAD-dependent transcription impaired
- Cross-talk with [ER stress](/mechanisms/er-stress-neurodegeneration) pathways
Hippo Pathway and Neuroinflammation
Microglial Hippo Signaling
The Hippo pathway regulates microglial function:
YAP in [microglia](/cell-types/microglia-neuroinflammation) — Controls inflammatory gene expression
MST1 regulation — Mediates cytokine-induced apoptosis
Cross-talk with [NF-κB](/entities/nf-kb) — Coordinates inflammatory responseTherapeutic Targeting
Hippo pathway modulators may reduce neuroinflammation:
- YAP agonists reduce microglial activation
- MST1 inhibitors protect neurons from inflammatory death
YAP/TAZ in Neuroprotection
Mechanistic Insights
YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) serve as key transcriptional effectors of the Hippo pathway with significant neuroprotective functions[@hansen2021]:
Pro-survival gene expression: YAP/TAZ translocate to the nucleus and activate genes promoting neuronal survival
Anti-apoptotic signaling: Direct activation of Bcl-2 family genes
Metabolic regulation: Enhancement of mitochondrial function
Autophagy modulation: Regulation of autophagic fluxYAP Nuclear Localization
In neurodegeneration, YAP nuclear localization is compromised:
- AD: Reduced nuclear YAP in prefrontal cortex[@zhao2022]
- PD: α-Synuclein accumulation prevents YAP nuclear translocation[@yang2023]
- ALS: TDP-43 pathology disrupts YAP/TAZ signaling
Therapeutic Activation
Strategies to restore YAP/TAZ activity include:
- Pharmacological activators: Small molecules promoting nuclear localization
- Viral gene therapy: AAV-mediated YAP delivery
- Kinase inhibitors: MST1/2 inhibitors to prevent YAP phosphorylation
Ferroptosis Connection
New Insights
Recent research has revealed a critical connection between Hippo signaling and ferroptosis, a form of iron-dependent cell death[@wang2024]:
MST1 promotes ferroptosis: Activated MST1 enhances lipid peroxidation
YAP protects against ferroptosis: Nuclear YAP promotes antioxidant gene expression
Lats1/2 ablation paradoxically protective: Loss of Lats1/2 increases neuronal resilience against ferroptosis through unphosphorylated YAP[@inhibition]Therapeutic Implications
- YAP activators may reduce ferroptotic cell death
- Ferroptosis inhibitors may act partly through Hippo pathway modulation
- Combination approaches targeting both pathways show promise
Molecular Mechanisms in Detail
MST1 Kinase Signaling
MST1 (Mammalian STE20-like protein kinase 1) is a central mediator of stress-induced neuronal death[@uhl2020]:
Activation triggers:
- Oxidative stress
- Mitochondrial dysfunction
- DNA damage
- Aβ toxicity
- α-Synuclein pathology
Downstream targets:
- FOXO transcription factors
- p53-dependent apoptosis
- JNK pathway activation
- Autophagy regulation
LATS1/2 Kinase Function
LATS1/2 (Large tumor suppressor kinases) phosphorylate YAP/TAZ:
- Phosphorylation sites: YAP Ser127, TAZ Ser89
- Nuclear export: Phosphorylated YAP/TAZ retained in cytoplasm
- Degradation: Subsequent proteasomal degradation
YAP/TAZ Transcriptional Partners
| Partner | Function | Neurodegeneration Relevance |
|---------|----------|-----------------------------|
| TEAD1-4 | Pro-survival gene activation | Reduced in AD |
| SMADs | TGF-β signaling | Altered in PD |
| p73 | Apoptosis regulation | Impaired in ALS |
| Runx1 | Differentiation | Dysregulated |
Therapeutic Strategies
Pharmacological Approaches
| Compound | Target | Mechanism | Development Stage |
|----------|--------|-----------|-------------------|
| Xmu-mp-1 | MST1 | Kinase inhibitor | Preclinical[@xmump] |
| Verteporfin | YAP-TEAD | Interaction inhibitor | Research |
| CBL-0137 | YAP | Nuclear translocation | Preclinical |
| Dexamethasone | MST1 | Kinase modulation | Preclinical |
Gene Therapy Approaches
- Viral delivery of YAP/TAZ
- MST1 siRNA
- TEAD expression constructs
Clinical Development
Several compounds are in various stages of development[@chiang2024]:
| Agent | Target | Stage | Indication |
|-------|--------|-------|------------|
| Xmu-mp-1 | MST1 | Preclinical | AD |
| Verteporfin | YAP-TEAD | Research | PD |
| CBL-0137 | YAP | Preclinical | ALS |
Challenges and Considerations
- Blood-brain barrier penetration
- Target specificity
- Off-target effects
- Optimal delivery methods
Cross-Pathway Interactions
mTOR-Hippo Axis
The Hippo pathway intersects with mTOR signaling in neurodegeneration:
mTOR regulates Hippo: Active mTOR inhibits LATS1/2
Hippo affects mTOR: YAP/TAZ influence mTORC1 activity
Therapeutic targeting: Dual inhibition shows synergyAutophagy Connection
YAP/TAZ regulate autophagic genes:
- TFEB activation: YAP promotes TFEB nuclear translocation
- Lysosomal function: Enhanced autolysosome formation
- α-Synuclein clearance: Improved autophagy of pathological proteins
Mitochondrial Dynamics
Hippo pathway influences mitochondrial function:
- MST1 inhibits PGC-1α: Reduces mitochondrial biogenesis
- YAP promotes mitophagy: Through BNIP3L expression
- Energy metabolism: Altered ATP production
Research Pipeline and Future Directions
Ongoing Clinical Trials
- YAP modulators in preclinical development
- MST1 inhibitors in early-phase trials
- Gene therapy approaches for YAP delivery
Biomarker Development
- YAP nuclear localization as biomarker
- MST1 activity measurements
- YAP target gene expression profiling
Combination Therapies
- YAP activators with antioxidants
- MST1 inhibitors with ferroptosis modulators
- Gene therapy with small molecules
See Also
- [YAP Gene](/genes/yap1)
- [WWTR1 Gene](/genes/wwtr1)
- [TEAD1 Gene](/genes/tead1)
- [MST1 Kinase](/entities/mst1-kinase)
- [LATS1 Kinase](/entities/lats1-kinase)
- [Cellular Senescence](/mechanisms/cellular-senescence)
- [Apoptosis Pathway](/mechanisms/intrinsic-apoptosis-neurodegeneration)
- [mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration)
- [Autophagy Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
References
[Qin X, et al., Xmu-mp-1 attenuates streptozotocin-induced neurotoxicity in SH-SY5Y cells (2024)](https://pubmed.ncbi.nlm.nih.gov/41686328/)
[Wang L, et al., A metabolic cell death program downstream of SARM1 (2024)](https://pubmed.ncbi.nlm.nih.gov/41364765/)
[Xie Y, et al., Inhibition of Hippo Signaling Through Ablation of Lats1 and Lats2 Protects Against Cognitive Decline in 5xFAD Mice (2024)](https://pubmed.ncbi.nlm.nih.gov/40923675/)
[Zhang M, et al., An unrecognized mechanism of self-protection in degenerating neurons mediated by astrocytic YAP (2024)](https://pubmed.ncbi.nlm.nih.gov/40860154/)
[Li W, et al., Neuroprotective role of Hippo signaling by microtubule stability control (2024)](https://pubmed.ncbi.nlm.nih.gov/40178516/)
[Uhl M, et al., Hippo pathway kinases in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32829482/)
[Hansen M, et al., YAP/TAZ signaling in neuronal stress response and neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34471275/)
[Zhao L, et al., Hippo pathway dysregulation in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35642093/)
[Deggau M, et al., Targeting MST1 kinase in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37532456/)
[Chiang AC, et al., Modulators of YAP/TAZ activity as neuroprotective agents (2024)](https://pubmed.ncbi.nlm.nih.gov/38789234/)
[Yang C, et al., Hippo pathway in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37433719/)
[Gupta P, et al., Hippo pathway kinases as therapeutic targets in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38264018/)
[Liu L, et al., YAP-mediated neuroprotection in tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35659911/)
[Wang J, et al., Ferroptosis and the Hippo pathway (2024)](https://pubmed.ncbi.nlm.nih.gov/39012789/)Pathway Diagram
The following diagram shows the key molecular relationships involving Hippo Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)